Donaco International Limited

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 55.5M. In comparison, ALL.AX has a market cap of 28.9B. Regarding current trading prices, DNA.AX is priced at A$0.05, while ALL.AX trades at A$47.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.50, whereas ALL.AX's P/E ratio is 25.23. In terms of profitability, DNA.AX's ROE is +0.27%, compared to ALL.AX's ROE of +0.24%. Regarding short-term risk, DNA.AX is more volatile compared to ALL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA.AX.Check ALL.AX's competition here

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 55.5M. In comparison, TLC.AX has a market cap of 12.4B. Regarding current trading prices, DNA.AX is priced at A$0.05, while TLC.AX trades at A$5.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.50, whereas TLC.AX's P/E ratio is 34.88. In terms of profitability, DNA.AX's ROE is +0.27%, compared to TLC.AX's ROE of +1.10%. Regarding short-term risk, DNA.AX is more volatile compared to TLC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA.AX.Check TLC.AX's competition here

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 55.5M. In comparison, LNW.AX has a market cap of 9.9B. Regarding current trading prices, DNA.AX is priced at A$0.05, while LNW.AX trades at A$123.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.50, whereas LNW.AX's P/E ratio is 26.58. In terms of profitability, DNA.AX's ROE is +0.27%, compared to LNW.AX's ROE of +0.48%. Regarding short-term risk, DNA.AX is more volatile compared to LNW.AX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA.AX.Check LNW.AX's competition here

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 55.5M. In comparison, TAH.AX has a market cap of 2.1B. Regarding current trading prices, DNA.AX is priced at A$0.05, while TAH.AX trades at A$0.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.50, whereas TAH.AX's P/E ratio is 93.50. In terms of profitability, DNA.AX's ROE is +0.27%, compared to TAH.AX's ROE of +0.03%. Regarding short-term risk, DNA.AX is less volatile compared to TAH.AX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA.AX.Check TAH.AX's competition here

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 55.5M. In comparison, JIN.AX has a market cap of 494.6M. Regarding current trading prices, DNA.AX is priced at A$0.05, while JIN.AX trades at A$7.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.50, whereas JIN.AX's P/E ratio is 13.02. In terms of profitability, DNA.AX's ROE is +0.27%, compared to JIN.AX's ROE of +0.31%. Regarding short-term risk, DNA.AX is less volatile compared to JIN.AX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA.AX.Check JIN.AX's competition here

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 55.5M. In comparison, SKC.AX has a market cap of 489.4M. Regarding current trading prices, DNA.AX is priced at A$0.05, while SKC.AX trades at A$0.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.50, whereas SKC.AX's P/E ratio is 18.83. In terms of profitability, DNA.AX's ROE is +0.27%, compared to SKC.AX's ROE of +0.02%. Regarding short-term risk, DNA.AX is less volatile compared to SKC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA.AX.Check SKC.AX's competition here

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 55.5M. In comparison, SGR.AX has a market cap of 367.6M. Regarding current trading prices, DNA.AX is priced at A$0.05, while SGR.AX trades at A$0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.50, whereas SGR.AX's P/E ratio is -1.44. In terms of profitability, DNA.AX's ROE is +0.27%, compared to SGR.AX's ROE of -0.57%. Regarding short-term risk, DNA.AX is less volatile compared to SGR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA.AX.Check SGR.AX's competition here

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 55.5M. In comparison, PBH.AX has a market cap of 347.6M. Regarding current trading prices, DNA.AX is priced at A$0.05, while PBH.AX trades at A$1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.50, whereas PBH.AX's P/E ratio is -14.29. In terms of profitability, DNA.AX's ROE is +0.27%, compared to PBH.AX's ROE of +6.53%. Regarding short-term risk, DNA.AX is less volatile compared to PBH.AX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA.AX.Check PBH.AX's competition here

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 55.5M. In comparison, AGI.AX has a market cap of 336.8M. Regarding current trading prices, DNA.AX is priced at A$0.05, while AGI.AX trades at A$1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.50, whereas AGI.AX's P/E ratio is -16.67. In terms of profitability, DNA.AX's ROE is +0.27%, compared to AGI.AX's ROE of -0.06%. Regarding short-term risk, DNA.AX is less volatile compared to AGI.AX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA.AX.Check AGI.AX's competition here

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 55.5M. In comparison, BET.AX has a market cap of 196M. Regarding current trading prices, DNA.AX is priced at A$0.05, while BET.AX trades at A$0.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.50, whereas BET.AX's P/E ratio is -17.50. In terms of profitability, DNA.AX's ROE is +0.27%, compared to BET.AX's ROE of -0.13%. Regarding short-term risk, DNA.AX is less volatile compared to BET.AX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA.AX.Check BET.AX's competition here

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 55.5M. In comparison, BBT.AX has a market cap of 177M. Regarding current trading prices, DNA.AX is priced at A$0.05, while BBT.AX trades at A$0.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.50, whereas BBT.AX's P/E ratio is -3.40. In terms of profitability, DNA.AX's ROE is +0.27%, compared to BBT.AX's ROE of -0.23%. Regarding short-term risk, DNA.AX is less volatile compared to BBT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA.AX.Check BBT.AX's competition here

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 55.5M. In comparison, RCT.AX has a market cap of 169.3M. Regarding current trading prices, DNA.AX is priced at A$0.05, while RCT.AX trades at A$3.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.50, whereas RCT.AX's P/E ratio is 15.45. In terms of profitability, DNA.AX's ROE is +0.27%, compared to RCT.AX's ROE of +0.49%. Regarding short-term risk, DNA.AX is less volatile compared to RCT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA.AX.Check RCT.AX's competition here

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 55.5M. In comparison, AQS.AX has a market cap of 35.2M. Regarding current trading prices, DNA.AX is priced at A$0.05, while AQS.AX trades at A$0.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.50, whereas AQS.AX's P/E ratio is 19.00. In terms of profitability, DNA.AX's ROE is +0.27%, compared to AQS.AX's ROE of -0.15%. Regarding short-term risk, DNA.AX is less volatile compared to AQS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA.AX.Check AQS.AX's competition here